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vascular risk factors used in the economic model. A Markov
decision-analytic model using the Monte-Carlo simulation was
employed to examine cost-effectiveness. Hypothetical patients
were subject to risk of type 2 diabetes, CVD and stroke. Dia-
betic patients were at added risk of amputation, blindness 
and renal failure. Simulation of events was performed using 
the Framingham Heart Study and the UK Prospective Diabetes
Study. RESULTS: Signiﬁcant clinical beneﬁts were demonstrated
with sibutramine and diet/exercise compared with diet/exercise
alone: proportion of patients achieving ≥5% weight loss (51.6
vs 22.3% respectively; p < 0.0001), BMI (−1.65 [−1.97, −1.34]
kg/m2; p < 0.0005), absolute weight (−3.84 [−5.18, −2.49] kg; p
< 0.0005), HDL (4.07 [1.50, 6.65] mmol/L; p = 0.002) and
triglycerides (−12.17 [−21.82, −2.52]; p = 0.013). Small increases
in blood pressure (1–3 mmHg) and heart rate (4–5 beats/minute)
were observed. Sibutramine was a cost-effective addition 
to diet/exercise (approximately AUD$40,000 per additional
QALY). Sensitivity analyses demonstrated the model to be
robust. CONCLUSIONS: Sibutramine is a safe, effective, and
cost-effective intervention in the prevention of obesity-related
complications through weight loss and weight maintenance.
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For observational studies derived from Internet based cohorts,
the representativeness of demographic, behavioral and health
characteristics of subjects is not well-established in European
countries. OBJECTIVES: To compare distributions of self-
reported characteristics of subjects recruited via Internet in
Germany & UK to a national representative sample in each
country. METHODS: PROCEED is a multinational observa-
tional cohort of overweight & obese subjects (body mass index
>25 kg/m2) recruited through an existing Internet panel in
Germany & the UK in 2005. Eligibility criteria were: age 35–75;
not pregnant; willing to lose weight in the next year and weight
< 180 kg. Recruitment was stratiﬁed to balance gender and over-
weight and obese categories. Baseline demographics and selected
health and behavior characteristics of the PROCEED cohort
were compared with estimates from a relevant subset (same age,
BMI and not pregnant) of two National Surveys (1998 GNHIS
and 2003 HSE). PROCEED data were standardized for gender
and BMI category in each of the national surveys. RESULTS:
PROCEED subjects in Germany (n = 203) and the UK (n = 216)
presented similar characteristics to each national survey popula-
tion in terms of level of alcohol consumption, and prevalence 
of hypertension, high cholesterol and diabetes. More PROCEED
subjects reported having college or higher education (22% versus
12% in Germany; 31% versus 15% in the UK). PROCEED 
subjects were also more likely to be single. The German
PROCEED cohort had a higher proportion of current smokers
compared to GNHIS data (48% versus 24%) while the UK
PROCEED cohort was very similar to HSE data. CONCLU-
SIONS: Despite few differences in education level, marital and
smoking status, most demographic and health characteristics
were similar between the Internet cohort of overweight/obese
subjects and the German and UK national surveys.The internet
seems to be an appropriate tool for recruiting subjects in obser-
vational studies.
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OBJECTIVES: The objective was to examine the relationship
between changes in body weight and determine if there was causal
association with corresponding changes in health-related utility
measured by EQ5Dindex. METHODS: Data were extracted from
the Health Outcomes Data Repository (HODaR). Data from sub-
jects with multiple surveys were included. Analyses were con-
ducted to determine the relationship between changes in weight
and associated change in utility; overall and for different age, sex,
body mass index (BMI) and disease groups. RESULTS: The total
number of patients included was 8,286. The mean number of
completed questionnaires was 2.25. The mean time between ques-
tionnaires was 500 days (inter-quartile range [IQR], 1120). The
mean weight change was −0.027 kg (IQR = 5 kg). Weight did not
change in 19.8% of men and 18.3% of women. For men and
women, respectively, weight changed more than 3 kg in 35.3%
and 37.6%, more than 5 kg in 22.2% and 23.2% and more than
10 kg in 5.9% and 5.7%. An association between health utility
and weight gain could only be veriﬁed in high BMI groups (obese
class I–III; i.e. BMI > 30 kg/m2) with high weight gain (5 kg, 
10 kg). In these categories in men health utility decreased between
0.058 units (weight gain >5 kg, obese I) and 0.590 units (weight
gain >10 kg, obese I) in comparison to −0.006 (weight change up
to 5 kg, obese I) and −0.092 (weight change up to 5 kg, obese III)
for patients with lower weight change. In women these values
varied between 0.025 units (weight gain >5 kg, obese II) and 0.060
(weight gain >10 kg, obese II) and −0.001 (weight change up to
5 kg, obese II) and 0.017 (weight change up to 10 kg, obese I).
CONCLUSION: A negative relationship between weight gain and
health utility was veriﬁed. This relationship depended on the
initial weight and the magnitude of weight change.
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OBJECTIVES: Weight gain is a common side effect of many ther-
apies for type 2 diabetes (T2DM). This study reviews the medical
literature to summarize the consequences of weight gain on
health-related quality of life. METHODS: A review of the
medical literature, including MEDLINE, EMBASE, PsycINFO,
and abstracts from professional conferences, was conducted to
identify studies assessing the impact of body weight on patient
utility. Similarities and differences in study methodology and
results were evaluated. RESULTS: Seventeen papers presented
either: a) utility values by BMI or body weight or b) the change
in utility scores or QALYs based on unit changes in BMI or body
weight. Regardless of the patient population or methodology
used to elicit utility scores, all studies reviewed found as body
weight increased, patient utility decreased. Utility scores
obtained using standard gamble techniques were generally higher
than those using Time Trade Off or the EQ-5D. Most studies
evaluated utility scores stratiﬁed by body weight or BMI and
used regression analyses to attribute the difference in utility
scores to differences in weight while controlling for other factors.
Two studies used standard gamble methodology to evaluate the
change in utility scores by asking patients to evaluate the impact
of speciﬁc amounts of weight gain or loss. Studies generally
A327Abstracts
assumed a constant change in utility occurs with a one unit
change in BMI. However, recent studies demonstrate the magni-
tude of changes in utility scores may vary depending on: a)
whether a patient is valuing weight loss or gain; b) whether a
smaller or larger change in body weight is being evaluated; and
c) baseline BMI. CONCLUSIONS: Various utility values associ-
ated with body weight using different methodologies have been
published. Careful consideration should be given to determine
the most appropriate utility values to use in cost utility analyses
of T2DM therapies.
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OBJECTIVES: To develop a multidimensional speciﬁc question-
naire of factors related to weight loss therapies proposed for the
assessment of therapy success or failure. METHODS: Three focus
groups of patients where debriefed and an expert panel gathered
relevant issues and converted them into 54 items around 9 dimen-
sions: Alimentary Habits, Expectations towards Therapy, Effort
and Concern, Emotion, Conﬁdence, Believes, Motivation towards
Physical Exercise, Motivation towards Weight Loss, and Per-
ceived Control. Comprehension and legibility were questioned in
a pilot sample. A ﬁrst item reduction was done to avoid redun-
dancies and to establish content agreement. Item reduction was
carried out in a sample of patients using factor analysis. Feasi-
bility, reliability, content validity and factor validity were assessed.
RESULTS: A panel of 11 practitioners and researchers, belong-
ing to different health centers in the Community of Madrid gath-
ered 3 samples: One sample of 8 chronic patients participating in
3 focus groups; a sample of 8 patients to assess feasibility; a sample
of 121 patients for item reduction. A ﬁrst conceptual reduction
conveyed a 32 item version. After measurement in a representa-
tive sample a ﬁnal 17 items form was accepted. Items were
arranged around 6 dimensions: Impulsiveness, External Locus of
Control, Internal Locus of Control, Emotiveness, Motivation
towards Therapy and Exercise, and Personal Image. Overall
Cronbach’s a was 0.772 (ICC 95% conﬁdence interval =
0.698–0.835). The 6 dimensions solution accounted for 71.2%
of variance, with all eigenvalues above 1. CONCLUSIONS: The
new questionnaire is a very short inventory of factors which might
have screening properties in order to forecast the efﬁcacy of
weight loss therapies. Although further prospective research is
being carried out in order to assess predictive validity, basic psy-
chometric properties are good as a baseline model. Resulting
dimensions are meaningful and well formed.
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OBJECTIVES: To evaluate the impact of the ﬁrst selective
cannabinoid type 1 (CB1) receptor blocker, rimonabant, devel-
oped for the management of cardiometabolic risk factors, on
health related quality of life (HRQOL) in overweight/obese
patients with type 2 diabetes. METHODS: A total of 1045
patients with type 2 diabetes were randomized in a double-blind
trial and received either rimonabant 5 mg, 20 mg or placebo.
Patients completed the Impact of Weight on Quality of Life-Lite
(IWQOL-Lite), a validated 31-item questionnaire speciﬁcally
designed for HRQOL assessment in obesity, and reported days
missed from work at baseline and every 3-months up to 1 year.
Analyses were performed on mean score changes from baseline
to 1 year in the ITT population. Clinical meaningfulness was
assessed using the Effect Size (ES) method, which is a measure
of change over time that takes into account the variability within
the sample at baseline. RESULTS: At 1 year, patients adminis-
tered rimonabant 20 mg once daily (N = 339) reported signiﬁ-
cantly greater improvement (p < 0.001, and p = 0.03 for Work)
in IWQOL-Lite total score and 3 out of 5 domains (Physical
Function, Self-esteem and Work) than patients in the placebo
group (N = 348) (no signiﬁcant change in Sexual Life and Public
Distress). These improvements were clinically meaningful (ES >
0.2). Also, there was a trend to fewer days missed from work
reported by patients on rimonabant 20 mg (720 days) compared
with those on placebo (1242 days) over the study period (p =
0.2 based on the number of patients with at least 1 day missed
from work). CONCLUSIONS: HRQOL results showed both a
statistically signiﬁcant and clinically meaningful improvement in
total score and also several domains (Physical Function, Self-
esteem and Work) of the IWQOL-Lite questionnaire, with
rimonabant versus placebo after a once daily administration of
20 mg rimonabant in this population of overweight/obese
patients with diabetes.
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OBJECTIVES: To assess the efﬁcacy of a new, ready-to-use intra-
venous paracetamol in postoperative pain management in com-
parison with placebo, oral paracetamol, propacetamol and other
NSAIDs. METHODS: Electronic databases search (Medline—
PubMED, EMBASE, Cochrane Database of Systematic Reviews,
Cochrane Central Register of Controlled Trials, Core Biomedical
Collection), until March 2006, was conducted for randomised
controlled trials on postoperative pain management with intra-
venous paracetamol in monotherapy or in combined treatment.
Only full text articles published in peer-reviewed journals were
accepted. Study results were combined in meta-analysis plots
using RevMan, where appropriate. RESULTS: Six studies met the
inclusion criteria: four compared intravenous paracetamol with
placebo, one with oral paracetamol, two with propacetamol and
one with metamizole. All studies were methodologically of high
quality (average 4.83 points in Jadad scale). Treatment with intra-
venous paracetamol was signiﬁcantly superior to placebo in pain
relief, pain intensity difference, reduction of opioid consumption
and patient treatment satisfaction (by 22% to 325%). Patients
treated with intravenous paracetamol received less opioids than
treated with oral paracetamol, whereas incidence of postopera-
tive nausea and vomiting did not differ. No signiﬁcant difference
was obtained between intravenous paracetamol and propaceta-
